{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:49:51Z","timestamp":1760575791784,"version":"build-2065373602"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:00:00Z","timestamp":1606608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Good Liver Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jfma.2020.11.017","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T12:25:17Z","timestamp":1607689517000},"page":"1572-1580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8027","authenticated-orcid":false,"given":"Ling-Ying","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-8852","authenticated-orcid":false,"given":"Sang-Heng","family":"Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Yih","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Jung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Hueng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-0840","authenticated-orcid":false,"given":"Jang-Jaer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2020.11.017_bib1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jfma.2020.11.017_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.jfma.2020.11.017_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Canc J"},{"key":"10.1016\/j.jfma.2020.11.017_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0959-8049(97)10133-2","article-title":"Myeloma bone disease","volume":"34","author":"Mundy","year":"1998","journal-title":"Eur J Canc"},{"key":"10.1016\/j.jfma.2020.11.017_bib5","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jfma.2020.11.017_bib6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jfma.2020.11.017_bib7","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.jfma.2020.11.017_bib8","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2020.11.017_bib9","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Canc J"},{"key":"10.1016\/j.jfma.2020.11.017_bib10","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jfma.2020.11.017_bib11","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jfma.2020.11.017_bib12","first-page":"267","article-title":"Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities","volume":"2","author":"Cl\u00e9zardin","year":"2013","journal-title":"Bone Key Rep"},{"key":"10.1016\/j.jfma.2020.11.017_bib13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1248\/yakushi.132.1025","article-title":"Effect of bisphosphonates on anticancer activity in prostate cancer cells","volume":"132","author":"Iguchi","year":"2012","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.jfma.2020.11.017_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jfma.2020.11.017_bib15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw-2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jfma.2020.11.017_bib18","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphanates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2020.11.017_bib19","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2020.11.017_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.joms.2012.12.005","article-title":"Pamidronate enhances bacterial adhesion to bone hydroxyapatite. another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?","volume":"71","author":"Kos","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.jfma.2020.11.017_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.jfma.2020.11.017_bib23","first-page":"53","article-title":"Bisphosphonate - related osteonecrosis of the jaws: the point of view of the oral pathologist","volume":"4","author":"Ficarra","year":"2007","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.jfma.2020.11.017_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jcms.2010.05.009","article-title":"Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence-a multi-centre study","volume":"39","author":"Otto","year":"2011","journal-title":"J Cranio-Maxillo-Fac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.jfma.2020.11.017_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Anonymous","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2020.11.017_bib27","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"Anonymous","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2020.11.017_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s002230020042","article-title":"Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I","volume":"69","author":"Reginster","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jfma.2020.11.017_bib29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/hed.23235","article-title":"Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study","volume":"35","author":"Lee","year":"2013","journal-title":"Head Neck"},{"key":"10.1016\/j.jfma.2020.11.017_bib30","first-page":"e788","article-title":"The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw","volume":"22","author":"Eguchi","year":"2017","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.jfma.2020.11.017_bib31","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/jbmr.3191","article-title":"Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis","volume":"32","author":"Hayashida","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jfma.2020.11.017_bib32","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","article-title":"Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review","volume":"44","author":"Fliefel","year":"2015","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib33","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.joms.2007.03.006","article-title":"Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy","volume":"65","author":"Wang","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jfma.2020.11.017_bib34","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jfma.2020.11.017_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5001\/omj.2013.02","article-title":"Multiple myeloma: an update","volume":"28","author":"Al-Farsi","year":"2013","journal-title":"Oman Med J"},{"key":"10.1016\/j.jfma.2020.11.017_bib36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jfma.2020.11.017_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10183","article-title":"Epigenetic-based mechanisms of osteoblast suppression in multiple myeloma bone disease","volume":"3","author":"Adamik","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.jfma.2020.11.017_bib38","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2020.11.017_bib39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.0954-6820.1982.tb01976.x","article-title":"Bone scintigraphy in the diagnosis of skeletal involvement and metastatic calcification in multiple myeloma","volume":"211","author":"Nilsson-Ehle","year":"1982","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.jfma.2020.11.017_bib40","doi-asserted-by":"crossref","first-page":"s94","DOI":"10.1016\/j.joms.2015.09.024","article-title":"Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw","volume":"73","author":"Ruggiero","year":"2015","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620305945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620305945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:44:29Z","timestamp":1760539469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620305945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0929664620305945"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.11.017","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis of medication-related osteonecrosis of the jaws in cancer patients using antiresorptive agent zoledronic acid","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}